{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:39:43Z","timestamp":1784151583082,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-021-22142-y","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T11:03:43Z","timestamp":1616411023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The therapeutic implications of the genomic analysis of malignant pleural mesothelioma"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-5790","authenticated-orcid":false,"given":"Marjorie G.","family":"Zauderer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"22142_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","volume":"11","author":"F Galateau-Salle","year":"2016","unstructured":"Galateau-Salle, F., Churg, A., Roggli, V. & Travis, W. D. The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J. Thorac. Oncol. 11, 142\u2013154 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"22142_CR2","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler, H. L. et al. Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline. J. Clin. Oncol. 36, 1343\u20131373 (2018).","journal-title":"J. Clin. Oncol."},{"key":"22142_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668\u2013672 (2011).","journal-title":"Nat. Genet."},{"key":"22142_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"22142_CR5","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548\u20131565 (2018).","journal-title":"Cancer Discov."},{"key":"22142_CR6","doi-asserted-by":"publisher","unstructured":"Zhang, M. et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat. Commun https:\/\/doi.org\/10.1038\/s41467-021-21798-w (2021).","DOI":"10.1038\/s41467-021-21798-w"},{"key":"22142_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375\u2013386 (2021).","journal-title":"Lancet"},{"key":"22142_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731\u2013739 (2018).","journal-title":"N. Engl. J. Med."},{"key":"22142_CR9","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","volume":"35","author":"E Beddowes","year":"2017","unstructured":"Beddowes, E. et al. Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1\u2013deficient thoracic cancers. J. Clin. Oncol. 35, 1778\u20131785 (2017).","journal-title":"J. Clin. Oncol."},{"key":"22142_CR10","doi-asserted-by":"publisher","first-page":"8515","DOI":"10.1200\/JCO.2018.36.15_suppl.8515","volume":"36","author":"MG Zauderer","year":"2018","unstructured":"Zauderer, M. G. et al. Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R\/R) malignant mesothelioma (MM) with BAP1 inactivation. J. Clin. Oncol. 36, 8515\u20138515 (2018).","journal-title":"J. Clin. Oncol."},{"key":"22142_CR11","doi-asserted-by":"publisher","unstructured":"Fennell D. A. et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir. Med. https:\/\/doi.org\/10.1016\/S2213-2600(20)30390-8 (2021).","DOI":"10.1016\/S2213-2600(20)30390-8"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22142-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22142-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22142-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T11:32:44Z","timestamp":1669980764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22142-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["22142"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-22142-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the last 3 years, Dr. Zauderer has received consulting fees from Takeda, GlaxoSmithKline, Aldeyra Therapeutics, Novocure, and Atara and honoraria from Research to Practice, Medical Learning Institute and OncLive. Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium, Curis, Atara, and Roche for research conducted by Dr. Zauderer. Dr. Zauderer serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1819"}}